Brokerage Firm Rating Update on bluebird bio (BLUE)

bluebird bio (BLUE) : Zacks Investment Research ranks bluebird bio (BLUE) as 3, which is a Hold recommendation. 9 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 1.5, which indicates as a Strong Buy.

bluebird bio (BLUE) : Average target price received by bluebird bio (BLUE) is $78.5 with an expected standard deviation of $25.04. The most aggressive target on the stock is $117, whereas the most downbeat target is $42. 10 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Also, Cantor Fitzgerald initiates coverage on bluebird bio (NASDAQ:BLUE). In the latest research report, Cantor Fitzgerald announces the target price to $42 per share. According to the latest information available, the shares are now rated Hold by the analysts at the agency. The rating by the firm was issued on June 2, 2016.

bluebird bio (NASDAQ:BLUE): The stock opened at $50.87 and touched an intraday high of $52.9099 on Wednesday. During the day, the stock corrected to an intraday low of $50.87, however, the bulls stepped in and pushed the price higher to close in the green at $52.81 with a gain of 4.26% for the day. The total traded volume for the day was 673,815. The stock had closed at $50.65 in the previous trading session.

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.